



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

1614  
TECH CENTER 16002900

RECEIVED  
JAN 24 2003

Application of : Kevin Cusack et al.  
Serial No. : 09/777,554  
Filed : February 6, 2001  
Entitled : BENZOTHAZOLE DERIVATIVES  
Attorney Docket No. BBC-077/A

ART UNIT: 1614  
EXAMINER: Gerstl

Asst. Commissioner for Patents  
Washington, D.C. 20231

**Certificate of First Class Mailing (37 CFR 1.8(a))**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

1/17/03  
Date of Signature and of Mail Deposit

By:

**TRANSMITTAL LETTER**

Sir/Madam:

Transmitted herewith are: ☒ Reply Under 37 C.F.R. §1.111; and ☒ An Acknowledgement Postcard; to be filed in the above-identified patent application.

**FEE FOR ADDITIONAL CLAIMS**

- ☒ A fee for additional claims is not required.  
☐ A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEES DUE
TOTAL CLAIMS			0	× \$18	= 0.00
INDEPENDENT			0	× \$84	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				+\$280	= 0.00
TOTAL FEES DUE					=


PAYMENT OF ADDITIONAL FEES

- ☒ [X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

PETITION FOR EXTENSION OF TIME

- ☐ [ ] Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith: ☐ [ ] \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1);  
☐ [ ] \$400.00 for response within second month pursuant to 37 CFR 1.17(a)(2);  
☐ [ ] \$920.00 for response within third month pursuant to 37 CFR 1.17(a)(3);  
☐ [ ] \$1,440.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4).  
☐ [ ] \$1,960.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5).
- ☒ [X] The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Gayle B. O'Brien  
Agent for Applicants  
Registration No. 48,812  
Abbott Bioresearch Center, Inc.  
100 Research Drive  
Worcester, MA 01605-4314  
Telephone: (508) 688-8053  
Telefax: (508) 688-8110



#11A  
m.m.  
1/29/03

PATENT  
Attorney Docket No. BBC-077A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: **Cusack et al** :  
APPLICATION NO.: **09/777,554** :  
FILED: **February 6, 2001** :  
FOR: **Benzothiazole Derivatives:** :  
-----

EXAMINER: Gerstl, Robert  
ART UNIT: 1626

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

RECEIVED  
JAN 24 2003  
TECH CENTER 1809/2800

REPLY UNDER 37 C.F.R. §1.111

This is in reply to the Office Action mailed October 17, 2002, the period for response thereto having been set to expire on January 17, 2003.

Please amend the above-identified application as follows: